SCHEMBL5130197

SCHEMBL5130197

CC(=O)OCCCn1c(SC2=COC(Cc3ccccc3)O2)nc2c(N)ncnc21

nearest known ligand 0.54

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
HSP90AA1 P07900 11/20 0.54
HSP90AB1 P08238 11/20 0.54
KMT2A Q03164 1/20 0.44
HSP90B1 P14625 6/20 0.42
MAPK1 P28482 1/20 0.40
HDAC3 O15379 1/20 0.39
HDAC4 P56524 1/20 0.39
HDAC1 Q13547 1/20 0.39
HDAC7 Q8WUI4 1/20 0.39
HDAC2 Q92769 1/20 0.39
HDAC10 Q969S8 1/20 0.39
HDAC11 Q96DB2 1/20 0.39
HDAC8 Q9BY41 1/20 0.39
HDAC6 Q9UBN7 1/20 0.39
HDAC9 Q9UKV0 1/20 0.39
HDAC5 Q9UQL6 1/20 0.39
ERBB2 P04626 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5131902 0.87 HSP90AA1 (0.49) HSP90AA1HSP90AB1HSP90B1MAPK1
SCHEMBL3124520 0.86 ADORA2A (0.46) HSP90AA1HSP90AB1HSP90B1MAPK1
SCHEMBL3122642 0.84 ADORA2A (0.53) HSP90AA1HSP90AB1HSP90B1MAPK1
SCHEMBL3124080 0.84 HSP90B1 (0.44) HSP90AA1HSP90AB1HSP90B1MAPK1
SCHEMBL3119617 0.82 MAPK1 (0.42) HSP90AA1HSP90AB1KMT2AHSP90B1MAPK1
SCHEMBL3121969 0.80 ADORA2A (0.48) HSP90AA1HSP90AB1KMT2AHSP90B1MAPK1
SCHEMBL3111452 0.79 ADORA2A (0.45) HSP90AA1HSP90AB1HSP90B1MAPK1
SCHEMBL5142342 0.78 HSP90AA1 (0.38) HSP90AA1HSP90AB1HSP90B1MAPK1
SCHEMBL5035593 0.72 HSP90AA1 (0.56) HSP90AA1HSP90AB1HSP90B1HDAC3HDAC4
SCHEMBL5130186 0.72 HSP90AB1 (0.56) HSP90AA1HSP90AB1HSP90B1HDAC3HDAC4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1962863-A2 ORALLY ACTIVE PURINE-BASED INHIBITORS OF HEAT SHOCK PROTEIN 90 Conforma Therapeutics Corporation (US) 2008-09-03 EP disclosed
WO-2007075572-A2 ORALLY ACTIVE PURINE-BASED INHIBITORS OF HEAT SHOCK PROTEIN 90 CONFORMA THERAPEUTICS CORPORATION (US) 2007-07-05 WO disclosed
US-20070129334-A1 Orally Active Purine-Based Inhibitors of Heat Shock Protein 90 CONFORMA THERAPEUTICS CORPORATION (US) 2007-06-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070129334-A1 Orally Active Purine-Based Inhibitors of Heat Shock Protein 90 HSP90AB1, HSP90AA1, HSP90AB2P HSP90AA1 2/4885HSP90AB1 1/4885KMT2A 4440/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.